Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. The rBCG vaccine, originally developed as a live vaccine against ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

The alternative BCG source has been developed by the Serum Institute of India, the world’s largest manufacturer of vaccines by volume. In bladder cancer clinical trials in Europe, the ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for ... combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients ...

in bladder cancer treatment. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive NMIBC. The company is known for its efforts in developing therapies and vaccines that augment the natural ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent immunogenicity ... potential benefits to patients, potential treatment outcomes for patients, the ...